Summary of Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings as of May 17, 2018

May 17, 2018 - By Jenna Rose

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.31. That’s change of 0.01, from 2017Q3’s 1.32. 7 investors sold all, 22 reduced holdings as Theravance Biopharma, Inc. ratio worsened. 26 rose stakes while 12 funds amassed stakes. Funds hold 35.06 million shares thus 1.11% less from 2017Q3’s 35.46 million shares.
California State Teachers Retirement Sys owns 65,835 shs for 0% of their capital. 18,950 were reported by Voya Mngmt Limited Liability. Parallax Volatility Advisers Lp owns 6,384 shs or 0% of their US capital. New York-based Millennium Mgmt Ltd Liability Corp has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Senzar Asset Mgmt Ltd Liability Corp invested in 1.22% or 171,800 shs. Bancorporation Of Montreal Can owns 693 shs for 0% of their capital. Barclays Public Limited Company reported 8,892 shs. State Street Corporation accumulated 883,096 shs. Schwab Charles Investment Mngmt Inc holds 0% or 199,677 shs. Manufacturers Life The holds 0% or 30,964 shs. Credit Suisse Ag invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Foundation Asset Management Limited Partnership has invested 3.63% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Teacher Retirement System Of Texas holds 14,931 shs. Citigroup Inc invested in 0% or 358 shs. 11,216 are owned by Landscape Mgmt Limited Liability Corporation.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

A total of 3 analysts rate Theravance Biopharma (NASDAQ:TBPH) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:TBPH) has 4 ratings reports on May 17, 2018 according to StockzIntelligence. On Thursday, March 29 the firm has “Buy” rating by Piper Jaffray given. On Tuesday, February 27 the stock has “Buy” rating by Cantor Fitzgerald. On Thursday, February 8 Leerink Swann maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating. Leerink Swann has “Outperform” rating and $48 target. On Tuesday, May 8 the stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

TBPH hit $24.35 during the last trading session after $0.32 change.Theravance Biopharma, Inc. has volume of 175,081 shares. Since May 17, 2017 TBPH has declined 26.76% and is downtrending. TBPH underperformed the S&P 500 by 38.31%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The firm is worth $1.34 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Last it reported negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by Prnewswire.com, Seekingalpha.com and Streetinsider.com. The first one has “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …” as a title and was published on April 20, 2018. The next is “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. And last was published on April 25, 2018, called “Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for …”.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.